Do analysts rate LONA or VYNE?

Athira Pharma presently has a consensus target price of $16.00, indicating a potential upside of 113.28%. Given Athira Pharma's stronger consensus rating and higher probable upside, equities analysts clearly believe Athira Pharma is more favorable than VYNE Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Athira Pharma 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50 VYNE Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media refer more to LONA or VYNE?

In the previous week, Athira Pharma had 1 more articles in the media than VYNE Therapeutics. MarketBeat recorded 2 mentions for Athira Pharma and 1 mentions for VYNE Therapeutics. Athira Pharma's average media sentiment score of 0.51 beat VYNE Therapeutics' score of -0.36 indicating that Athira Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Athira Pharma 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive VYNE Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate TLPH or VYNE?

Talphera presently has a consensus target price of $3.00, suggesting a potential upside of 112.16%. Given Talphera's stronger consensus rating and higher possible upside, equities research analysts plainly believe Talphera is more favorable than VYNE Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Talphera 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 VYNE Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media favor TLPH or VYNE?

In the previous week, Talphera had 4 more articles in the media than VYNE Therapeutics. MarketBeat recorded 5 mentions for Talphera and 1 mentions for VYNE Therapeutics. Talphera's average media sentiment score of 0.12 beat VYNE Therapeutics' score of -0.36 indicating that Talphera is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Talphera 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral VYNE Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend VYNE or SPRO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score VYNE Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Spero Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Does the media prefer VYNE or SPRO?

In the previous week, Spero Therapeutics had 3 more articles in the media than VYNE Therapeutics. MarketBeat recorded 4 mentions for Spero Therapeutics and 1 mentions for VYNE Therapeutics. Spero Therapeutics' average media sentiment score of 0.00 beat VYNE Therapeutics' score of -0.36 indicating that Spero Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment VYNE Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Spero Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate CLNN or VYNE?

Clene currently has a consensus target price of $33.25, indicating a potential upside of 631.57%. Given Clene's stronger consensus rating and higher probable upside, equities analysts clearly believe Clene is more favorable than VYNE Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Clene 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.71 VYNE Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is CLNN or VYNE more profitable?

VYNE Therapeutics has a net margin of -4,726.21% compared to Clene's net margin of -25,009.70%. Clene's return on equity of 0.00% beat VYNE Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Clene -25,009.70% N/A -137.98% VYNE Therapeutics -4,726.21% -70.42% -63.46%

Does the media favor CLNN or VYNE?

In the previous week, Clene had 2 more articles in the media than VYNE Therapeutics. MarketBeat recorded 3 mentions for Clene and 1 mentions for VYNE Therapeutics. Clene's average media sentiment score of 0.00 beat VYNE Therapeutics' score of -0.36 indicating that Clene is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Clene 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral VYNE Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer VYNE or MNOV?

MediciNova has a consensus price target of $8.33, indicating a potential upside of 528.93%. Given MediciNova's stronger consensus rating and higher possible upside, analysts clearly believe MediciNova is more favorable than VYNE Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score VYNE Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 MediciNova 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.67

Does the media prefer VYNE or MNOV?

In the previous week, MediciNova had 1 more articles in the media than VYNE Therapeutics. MarketBeat recorded 2 mentions for MediciNova and 1 mentions for VYNE Therapeutics. MediciNova's average media sentiment score of 0.00 beat VYNE Therapeutics' score of -0.36 indicating that MediciNova is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment VYNE Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral MediciNova 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

VYNE Therapeutics (VYNE) Competitors

$28.32 -0.24 (-0.82%)

Closing price 07/27/2026

Extended Trading

$28.32 0.00 (0.00%)

As of 07/27/2026 07:48 PM Eastern

Compare

VYNE vs. LONA, TLPH, SPRO, CLNN, and MNOV

Should you buy VYNE Therapeutics stock or one of its competitors? MarketBeat compares VYNE Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with VYNE Therapeutics include Athira Pharma (LONA), Talphera (TLPH), Spero Therapeutics (SPRO), Clene (CLNN), and MediciNova (MNOV). These companies are all part of the "pharmaceuticals" industry.

How does VYNE Therapeutics compare to Athira Pharma?

Athira Pharma (NASDAQ:LONA) and VYNE Therapeutics (NASDAQ:VYNE) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, risk, earnings, valuation, analyst recommendations, media sentiment, dividends and institutional ownership.

57.1% of Athira Pharma shares are owned by institutional investors. Comparatively, 83.8% of VYNE Therapeutics shares are owned by institutional investors. 25.7% of Athira Pharma shares are owned by company insiders. Comparatively, 3.0% of VYNE Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Athira Pharma has a beta of 2.05, suggesting that its share price is 105% more volatile than the broader market. Comparatively, VYNE Therapeutics has a beta of 2, suggesting that its share price is 100% more volatile than the broader market.

In the previous week, Athira Pharma had 1 more articles in the media than VYNE Therapeutics. MarketBeat recorded 2 mentions for Athira Pharma and 1 mentions for VYNE Therapeutics. Athira Pharma's average media sentiment score of 0.51 beat VYNE Therapeutics' score of -0.36 indicating that Athira Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Athira Pharma	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
VYNE Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Athira Pharma presently has a consensus target price of $16.00, indicating a potential upside of 113.28%. Given Athira Pharma's stronger consensus rating and higher probable upside, equities analysts clearly believe Athira Pharma is more favorable than VYNE Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Athira Pharma	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
VYNE Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

VYNE Therapeutics has higher revenue and earnings than Athira Pharma. VYNE Therapeutics is trading at a lower price-to-earnings ratio than Athira Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Athira Pharma	N/A	N/A	-$105.61M	-$5.21	N/A
VYNE Therapeutics	$570K	33.29	-$26.48M	-$0.38	N/A

Athira Pharma has a net margin of 0.00% compared to VYNE Therapeutics' net margin of -4,726.21%. VYNE Therapeutics' return on equity of -70.42% beat Athira Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Athira Pharma	N/A	-381.01%	-225.74%
VYNE Therapeutics	-4,726.21%	-70.42%	-63.46%

Summary

Athira Pharma beats VYNE Therapeutics on 9 of the 15 factors compared between the two stocks.

How does VYNE Therapeutics compare to Talphera?

Talphera (NASDAQ:TLPH) and VYNE Therapeutics (NASDAQ:VYNE) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, earnings, media sentiment, dividends, valuation and profitability.

Talphera has a net margin of 0.00% compared to VYNE Therapeutics' net margin of -4,726.21%. VYNE Therapeutics' return on equity of -70.42% beat Talphera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Talphera	N/A	-92.98%	-53.22%
VYNE Therapeutics	-4,726.21%	-70.42%	-63.46%

Talphera presently has a consensus target price of $3.00, suggesting a potential upside of 112.16%. Given Talphera's stronger consensus rating and higher possible upside, equities research analysts plainly believe Talphera is more favorable than VYNE Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Talphera	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
VYNE Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

37.7% of Talphera shares are held by institutional investors. Comparatively, 83.8% of VYNE Therapeutics shares are held by institutional investors. 3.5% of Talphera shares are held by insiders. Comparatively, 3.0% of VYNE Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Talphera has a beta of 0.69, indicating that its stock price is 31% less volatile than the broader market. Comparatively, VYNE Therapeutics has a beta of 2, indicating that its stock price is 100% more volatile than the broader market.

Talphera has higher earnings, but lower revenue than VYNE Therapeutics. VYNE Therapeutics is trading at a lower price-to-earnings ratio than Talphera, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Talphera	$1K	73,386.60	-$14.29M	-$0.31	N/A
VYNE Therapeutics	$570K	33.29	-$26.48M	-$0.38	N/A

In the previous week, Talphera had 4 more articles in the media than VYNE Therapeutics. MarketBeat recorded 5 mentions for Talphera and 1 mentions for VYNE Therapeutics. Talphera's average media sentiment score of 0.12 beat VYNE Therapeutics' score of -0.36 indicating that Talphera is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Talphera	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
VYNE Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Talphera beats VYNE Therapeutics on 12 of the 16 factors compared between the two stocks.

How does VYNE Therapeutics compare to Spero Therapeutics?

VYNE Therapeutics (NASDAQ:VYNE) and Spero Therapeutics (NASDAQ:SPRO) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, institutional ownership, analyst recommendations, media sentiment and risk.

Spero Therapeutics has a net margin of 24.90% compared to VYNE Therapeutics' net margin of -4,726.21%. Spero Therapeutics' return on equity of 35.58% beat VYNE Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
VYNE Therapeutics	-4,726.21%	-70.42%	-63.46%
Spero Therapeutics	24.90%	35.58%	24.95%

Spero Therapeutics has higher revenue and earnings than VYNE Therapeutics. VYNE Therapeutics is trading at a lower price-to-earnings ratio than Spero Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
VYNE Therapeutics	$570K	33.29	-$26.48M	-$0.38	N/A
Spero Therapeutics	$66.80M	1.08	$8.57M	$0.24	5.19

83.8% of VYNE Therapeutics shares are owned by institutional investors. Comparatively, 25.6% of Spero Therapeutics shares are owned by institutional investors. 3.0% of VYNE Therapeutics shares are owned by insiders. Comparatively, 2.9% of Spero Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Spero Therapeutics had 3 more articles in the media than VYNE Therapeutics. MarketBeat recorded 4 mentions for Spero Therapeutics and 1 mentions for VYNE Therapeutics. Spero Therapeutics' average media sentiment score of 0.00 beat VYNE Therapeutics' score of -0.36 indicating that Spero Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
VYNE Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Spero Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
VYNE Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Spero Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

VYNE Therapeutics has a beta of 2, suggesting that its share price is 100% more volatile than the broader market. Comparatively, Spero Therapeutics has a beta of 1.55, suggesting that its share price is 55% more volatile than the broader market.

Summary

Spero Therapeutics beats VYNE Therapeutics on 10 of the 14 factors compared between the two stocks.

How does VYNE Therapeutics compare to Clene?

Clene (NASDAQ:CLNN) and VYNE Therapeutics (NASDAQ:VYNE) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, media sentiment, risk, valuation and institutional ownership.

VYNE Therapeutics has a net margin of -4,726.21% compared to Clene's net margin of -25,009.70%. Clene's return on equity of 0.00% beat VYNE Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Clene	-25,009.70%	N/A	-137.98%
VYNE Therapeutics	-4,726.21%	-70.42%	-63.46%

Clene currently has a consensus target price of $33.25, indicating a potential upside of 631.57%. Given Clene's stronger consensus rating and higher probable upside, equities analysts clearly believe Clene is more favorable than VYNE Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Clene	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
VYNE Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

23.3% of Clene shares are owned by institutional investors. Comparatively, 83.8% of VYNE Therapeutics shares are owned by institutional investors. 28.3% of Clene shares are owned by insiders. Comparatively, 3.0% of VYNE Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Clene had 2 more articles in the media than VYNE Therapeutics. MarketBeat recorded 3 mentions for Clene and 1 mentions for VYNE Therapeutics. Clene's average media sentiment score of 0.00 beat VYNE Therapeutics' score of -0.36 indicating that Clene is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Clene	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
VYNE Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Clene has higher earnings, but lower revenue than VYNE Therapeutics. VYNE Therapeutics is trading at a lower price-to-earnings ratio than Clene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Clene	$200K	290.43	-$26.17M	-$3.20	N/A
VYNE Therapeutics	$570K	33.29	-$26.48M	-$0.38	N/A

Clene has a beta of 0.96, indicating that its stock price is 4% less volatile than the broader market. Comparatively, VYNE Therapeutics has a beta of 2, indicating that its stock price is 100% more volatile than the broader market.

Summary

Clene beats VYNE Therapeutics on 10 of the 16 factors compared between the two stocks.

How does VYNE Therapeutics compare to MediciNova?

VYNE Therapeutics (NASDAQ:VYNE) and MediciNova (NASDAQ:MNOV) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, profitability, risk, earnings, dividends and valuation.

In the previous week, MediciNova had 1 more articles in the media than VYNE Therapeutics. MarketBeat recorded 2 mentions for MediciNova and 1 mentions for VYNE Therapeutics. MediciNova's average media sentiment score of 0.00 beat VYNE Therapeutics' score of -0.36 indicating that MediciNova is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
VYNE Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
MediciNova	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

MediciNova has a consensus price target of $8.33, indicating a potential upside of 528.93%. Given MediciNova's stronger consensus rating and higher possible upside, analysts clearly believe MediciNova is more favorable than VYNE Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
VYNE Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
MediciNova	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

83.8% of VYNE Therapeutics shares are owned by institutional investors. Comparatively, 9.9% of MediciNova shares are owned by institutional investors. 3.0% of VYNE Therapeutics shares are owned by company insiders. Comparatively, 14.0% of MediciNova shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

VYNE Therapeutics has a beta of 2, suggesting that its share price is 100% more volatile than the broader market. Comparatively, MediciNova has a beta of 0.63, suggesting that its share price is 37% less volatile than the broader market.

MediciNova has a net margin of -1,962.98% compared to VYNE Therapeutics' net margin of -4,726.21%. MediciNova's return on equity of -27.28% beat VYNE Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
VYNE Therapeutics	-4,726.21%	-70.42%	-63.46%
MediciNova	-1,962.98%	-27.28%	-25.24%

MediciNova has higher revenue and earnings than VYNE Therapeutics. VYNE Therapeutics is trading at a lower price-to-earnings ratio than MediciNova, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
VYNE Therapeutics	$570K	33.29	-$26.48M	-$0.38	N/A
MediciNova	$596.64K	109.31	-$12M	-$0.23	N/A

Summary

MediciNova beats VYNE Therapeutics on 15 of the 17 factors compared between the two stocks.

Get VYNE Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VYNE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VYNE vs. The Competition

Export

Metric	VYNE Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$18.98M	$11.92B	$7.04B	$12.92B
Dividend Yield	N/A	2.69%	2.58%	10.20%
P/E Ratio	-74.54	788.54	269.97	24.82
Price / Sales	33.29	967.38	650.66	108.09
Price / Cash	N/A	15.12	28.89	37.44
Price / Book	0.68	10.33	11.26	6.44
Net Income	-$26.48M	$2.77B	$3.45B	$347.27M
7 Day Performance	N/A	1.99%	3.62%	2.55%
1 Month Performance	-11.15%	-1.56%	-0.56%	-1.02%
1 Year Performance	58.73%	191.17%	77.38%	23.33%

VYNE Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VYNE VYNE Therapeutics	0.6379 of 5 stars	$28.33 -0.8%	N/A	+58.7%	$18.98M	$570K	N/A	30	Upcoming Earnings Gap Down High Trading Volume
LONA Athira Pharma	3.5264 of 5 stars	$7.66 +2.5%	$16.00 +108.9%	N/A	$70.17M	N/A	N/A	40	News Coverage Analyst Forecast
TLPH Talphera	2.3651 of 5 stars	$1.36 +2.3%	$3.00 +120.6%	+249.2%	$69.03M	$30K	N/A	19	Upcoming Earnings Analyst Upgrade
SPRO Spero Therapeutics	0.98 of 5 stars	$1.23 +7.0%	N/A	-42.5%	$66.59M	$66.80M	5.13	150	Upcoming Earnings
CLNN Clene	2.0539 of 5 stars	$5.28 +1.7%	$33.25 +529.7%	+43.5%	$66.32M	$200K	N/A	100	News Coverage Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VYNE) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

VYNE Therapeutics (VYNE) Competitors

VYNE vs. LONA, TLPH, SPRO, CLNN, and MNOV

How does VYNE Therapeutics compare to Athira Pharma?

Summary

How does VYNE Therapeutics compare to Talphera?

Summary

How does VYNE Therapeutics compare to Spero Therapeutics?

Summary

How does VYNE Therapeutics compare to Clene?

Summary

How does VYNE Therapeutics compare to MediciNova?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VYNE vs. The Competition

VYNE Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

VYNE Therapeutics (VYNE) Competitors

VYNE vs. LONA, TLPH, SPRO, CLNN, and MNOV

How does VYNE Therapeutics compare to Athira Pharma?

Do institutionals & insiders believe in LONA or VYNE?

Which has more risk and volatility, LONA or VYNE?

Does the media refer more to LONA or VYNE?

Do analysts rate LONA or VYNE?

Which has higher earnings & valuation, LONA or VYNE?

Is LONA or VYNE more profitable?

Summary

How does VYNE Therapeutics compare to Talphera?

Is TLPH or VYNE more profitable?

Do analysts rate TLPH or VYNE?

Do insiders & institutionals believe in TLPH or VYNE?

Which has more risk and volatility, TLPH or VYNE?

Which has preferable valuation and earnings, TLPH or VYNE?

Does the media favor TLPH or VYNE?

Summary

How does VYNE Therapeutics compare to Spero Therapeutics?

Is VYNE or SPRO more profitable?

Which has better valuation and earnings, VYNE or SPRO?

Do institutionals and insiders have more ownership in VYNE or SPRO?

Does the media prefer VYNE or SPRO?

Do analysts recommend VYNE or SPRO?

Which has more risk and volatility, VYNE or SPRO?

Summary

How does VYNE Therapeutics compare to Clene?

Is CLNN or VYNE more profitable?

Do analysts rate CLNN or VYNE?

Do institutionals and insiders believe in CLNN or VYNE?

Does the media favor CLNN or VYNE?

Which has better earnings and valuation, CLNN or VYNE?

Which has more volatility and risk, CLNN or VYNE?

Summary

How does VYNE Therapeutics compare to MediciNova?

Does the media prefer VYNE or MNOV?

Do analysts prefer VYNE or MNOV?

Do insiders and institutionals believe in VYNE or MNOV?

Which has more volatility and risk, VYNE or MNOV?

Is VYNE or MNOV more profitable?

Which has better valuation & earnings, VYNE or MNOV?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VYNE vs. The Competition

VYNE Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools